Abstracts tagged "pediatric rheumatology and scleroderma"

Abstract Number: 2149 • 2018 ACR/ARHP Annual Meeting
Assessing the Prevalence of Localized Scleroderma in Childhood Using Dministrative Claims Data from the United States
Timothy Beukelman¹, Fenglong Xie² and Ivan Foeldvari³, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile Localised Scleroderma (jlSc) is believed a rare autoimmune disease, which occurs 10 times more often then systemic sclerosis in childhood and is believed…
Abstract Number: 1119 • 2018 ACR/ARHP Annual Meeting
Genetic Signatures from RNA Sequencing of Pediatric Localized Scleroderma (LS) Skin
Emily Mirizio¹, Roosha Mandal², Qi Yan³, William Horne⁴, Kaila Schollaert-Fitch³ and Kathryn S. Torok⁵, ¹Peds Rheum, University of Pittsburgh Med Ctr, Pittsburgh, PA, ²Carnegie Mellon University, Pittsburgh, PA, ³University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Health Sciences Sequencing Core at Children's Hospital of Pittsburgh, Pittsburgh, PA, ⁵Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA
Background/Purpose: Localized scleroderma (LS) is a progressive disease of the skin and underlying tissue that causes significant functional disability and disfigurement, especially in developing children.…
Abstract Number: 2346 • 2017 ACR/ARHP Annual Meeting
Chemokine Ligand 9 (CXCL9) [Monokine Induced By Gamma Interferon (MIG)] As a Predictor of Active Disease Status in Localized Scleroderma
Kathryn S. Torok¹, Qi Mi², Emily Mirizio³, Kaila Schollaert-Fitch¹, Mark Fritzler⁴ and Marvin J. Fritzler⁵, ¹Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ²Department of Sports Medicine and Nutrition, University of Pittsburgh, Pittsburgh, PA, ³Pediatric Rhuematology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Eve Technologies, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Localized scleroderma (LS) is a fibrotic autoimmune disease of the skin and underlying tissues which can lead to disfiguring sequlea, especially in childhood-onset. Untreated…
Abstract Number: 1023 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-a (TNF-a) and Interferon Gamma Inducible Protein-10 (IP-10) As Predictors of Active Disease Status in Localized Scleroderma
Kathryn S. Torok¹, Jonathan Yabes², Qi Mi³, Christina Kelsey¹ and Kelsey Magee⁴, ¹Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Department of Sports Medicine and Nutrition, University of Pittsburgh, Pittsburgh, PA, ⁴Pediatrics, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Localized scleroderma has both inflammatory and fibrotic components contributing to its effect on the skin and underlying tissue. The extent and duration of…
Abstract Number: 1897 • 2014 ACR/ARHP Annual Meeting
Circulating T-Helper Cell- Associated Cytokines and Chemokines in Localized Scleroderma
Kathryn S. Torok¹, Katherine Kurzinski², Christina Kelsey³, Kelsey Magee⁴, Jonathan Yabes⁵, Abbe N. Vallejo⁶, Thomas A. Medsger Jr.⁷ and Carol A. Feghali-Bostwick⁸, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh/UPMC, Pittsburgh, PA, ⁴Pediatric Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁶Department of Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Localized scleroderma (LS) is an autoimmune disease of the skin and underlying tissues which results in disfigurement and orthopedic complications, especially when the onset…
Abstract Number: 2029 • 2012 ACR/ARHP Annual Meeting
Reliability of Scoring a Disease Damage Measure for Juvenile Localized Scleroderma
Kathryn S. Torok¹, Suzanne C. Li², Christina Kelsey³, Mara L Becker⁴, Fatma Dedeoglu⁵, Robert C. Fuhlbrigge⁶, Gloria Higgins⁷, Sandy D. Hong⁸, Maria F. Ibarra⁹, Ronald Laxer¹⁰, Thomas G. Mason II¹¹, Marilynn G. Punaro¹², Elena Pope¹³, C. Egla Rabinovich¹⁴ and Katie G. Stewart¹², ¹Pediatric Rheumatology, Scleroderma Center of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pediatrics, Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ³Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO, ⁵Division of Immunology, Boston Children's Hospital, Boston, MA, ⁶Pediatric Rheumatology, Childrens Hospital, Boston, MA, ⁷Pediatric Rheumatology NATIONWIDE CHILDRENS HOSPITAL, PRCSG-Cincinnati Children's Hospital Medical Center, Columbus, OH, ⁸Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, ⁹Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ¹⁰Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Rheumatology, Mayo Clinic Rochester, Rochester, MN, ¹²Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹³Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Pediatric Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: . In order to more accurately capture disease activity and damage in juvenile Localized Scleroderma (jLS) and to develop an accepted outcome measure for…
Abstract Number: 2036 • 2012 ACR/ARHP Annual Meeting
Children’s Hospital of Pittsburgh Pediatric Onset En Coup De Sabre and Parry-Romberg Syndrome Cohort
Kristin M. Brown¹, Darren Smith², Christina Kelsey³, Katherine Kurzinski⁴ and Kathryn S. Torok⁵, ¹Pediatric Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Plastic and Reconstructive Surgery, university of Pittsburgh Division of Plastic and Reconstructive Surgery, Children's Hospital of Pittsburgh, Pittsburgh, ³Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁵Pediatric Rheumatology, Scleroderma Center of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
Background/Purpose: Localized scleroderma is an autoimmune disease characterized by disfiguring thickening and fibrosis of the skin and underlying soft tissues; the majority of cases have…
Abstract Number: 2008 • 2012 ACR/ARHP Annual Meeting
Initial Evaluation of a Localized Scleroderma (LS) Clinical Activity Measure
Suzanne C. Li¹, Kathryn S. Torok², Christina Kelsey³, Mara L Becker⁴, Fatma Dedeoglu⁵, Robert C. Fuhlbrigge⁶, Gloria C. Higgins⁷, Sandy D. Hong⁸, Maria F. Ibarra⁹, Ronald Laxer¹⁰, Thomas G. Mason II¹¹, Marilynn G. Punaro¹², Elena Pope¹³, C. Egla Rabinovich¹⁴ and Katie G. Stewart¹², ¹Pediatrics, Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Scleroderma Center of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO, ⁵Division of Immunology, Boston Children's Hospital, Boston, MA, ⁶Pediatric Rheumatology, Childrens Hospital, Boston, MA, ⁷Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ⁸Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, ⁹Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ¹⁰Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Rheumatology, Mayo Clinic Rochester, Rochester, MN, ¹²Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹³Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Pediatric Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: LS commonly causes severe morbidity for the growing child. Optimal therapy is not known and the lack of an agreed-upon standard for assessing disease…
Abstract Number: 319 • 2012 ACR/ARHP Annual Meeting
Gamma Interferon-Induced Protein-10 (IP-10) As a Potential Biomarker for Disease Activity in Pediatric Localized Scleroderma
Katherine Kurzinski¹, Carol A. Feghali-Bostwick², Christina Kelsey¹, Kelsey Magee³ and Kathryn S. Torok⁴, ¹Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Pediatric Rheumatology, Scleroderma Center of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
Background/Purpose: Pediatric localized scleroderma (LS) is an autoimmune disease affecting the skin and underlying tissue. Cutaneous findings assist in categorizing the patients into active or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].